Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Asperuloside (Asperulosid) 是一种来源于蛇舌草的环烯醚萜,具有抗炎作用。它可抑制诱导型一氧化氮合酶,抑制 NF-κB 和 MAPK 信号通路。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 219 | 现货 | ||
5 mg | ¥ 555 | 现货 | ||
10 mg | ¥ 927 | 现货 | ||
25 mg | ¥ 1,650 | 现货 | ||
50 mg | ¥ 2,470 | 现货 |
产品描述 | Asperuloside (Asperulosid) has anti-inflammatory activity. |
激酶实验 | The chemiluminescent assay is used to confirm PCSEE MAO-A and MAO-B inhibitory effects and to test BNN and BVN hMAO-A and hMAO-B inhibition using MAO-Glo kit. Each enzyme's Arbitrary Light Unit (ALU) is measured in the presence of PCSEE, BNN, BVN, and standard DEP as an MAO-BI positive control. Briefly, hMAO-A and hMAO-B isozymes are diluted to 2× with reaction buffer (pH 7.4) and preincubated with 4× PCSEE, BNN, BVN, or DEP working solutions at RT for 30?min in white opaque 96-well plates. For determining activity inhibition, final 8.5?μg/mL concentrations of PCSEE, BNN, BVN, and DEP are used. For IC50 determination, 8× PCSEE and BNN working solutions are serially diluted using reaction buffers (pH 7.4) to make a 4× concentration. Ten points' range of PCSEE (1.0 to 250.0?μg/mL) and BNN (up to 400?μM (135.4?μg/mL)) final concentrations is used. Controls used are with and without ethanol. Ethanol solvent in controls is kept to a maximum final (volume) of ≤2%. Each isozyme is substituted with the reaction buffer for the blank. Based on our preliminary optimizations and Valley's method, the reaction is initiated by adding 4× luciferin derivative substrate (LDS) for a final (concentration) of 40 and 4?μM for hMAO-A and hMAO-B reactions, respectively. The final volume per well of each reaction is 50?μL. The reaction is optimized for the amount of A and B enzyme used to be incubated for less than 3.5?h at RT. To stop the reaction and produce the luminescence signal RLDR is added to all wells, 50?μL to each well, and incubated for a further 30?min. |
别名 | Asperulosid, 车叶草苷 |
分子量 | 414.36 |
分子式 | C18H22O11 |
CAS No. | 14259-45-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (144.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4134 mL | 12.0668 mL | 24.1336 mL | 60.334 mL |
5 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL | 12.0668 mL | |
10 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL | 6.0334 mL | |
20 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL | 3.0167 mL | |
50 mM | 0.0483 mL | 0.2413 mL | 0.4827 mL | 1.2067 mL | |
100 mM | 0.0241 mL | 0.1207 mL | 0.2413 mL | 0.6033 mL |
中药材名称 | 中药材拉丁名 | 性 | 味 | 归经 |
八仙草 | Rubiae Radix Et Rhizoma | 寒 | 苦 | 肝, 胃 |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Asperuloside 14259-45-1 Immunology/Inflammation Others NO Synthase Inhibitor NOS Nitric oxide synthases Asperulosid 车叶草苷 inhibit inhibitor